- Home
- PRAX vs FLR Comparison
PRAX vs FLR Comparison
Compare PRAX & FLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | FLR |
|---|---|---|
| Founded | 2015 | 1912 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.9B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRAX | FLR |
|---|---|---|
| Price | $278.87 | $44.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $373.79 | $49.57 |
| AVG Volume (30 Days) | 580.2K | ★ 2.7M |
| Earning Date | 02-27-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1235.20 |
| EPS | N/A | ★ 20.04 |
| Revenue | $7,463,000.00 | ★ $15,587,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12,467.71 | $5.02 |
| P/E Ratio | ★ N/A | $2.21 |
| Revenue Growth | ★ 364.98 | N/A |
| 52 Week Low | $26.70 | $29.20 |
| 52 Week High | $317.72 | $57.50 |
Technical Indicators
Market Signals| Indicator | PRAX | FLR |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 58.35 |
| Support Level | $268.78 | $43.22 |
| Resistance Level | $305.21 | $45.50 |
| Average True Range (ATR) | 15.32 | 1.10 |
| MACD | -3.91 | 0.47 |
| Stochastic Oscillator | 20.68 | 85.25 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About FLR Fluor Corporation
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services.It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $16.3 billion in revenue in 2024.